Drug intelligence / Profile preview

NVG-291

Development stage: Phase 3
Lead developer: NervGen Pharma
Modality: Peptides
Administration: Subcutaneous

Overview

NVG-291 is a first-in-class therapeutic peptide developed by NervGen Pharma. It targets mechanisms that interfere with nervous system repair, particularly by addressing chondroitin sulfate proteoglycans (CSPGs) that form scars after injuries. NVG-291 is being evaluated for its potential to promote neural repair in conditions such as spinal cord injury, multiple sclerosis, Alzheimer's disease, and stroke. It is administered via subcutaneous injection.

Other names: ISPIntracellular Sigma Peptide

Targets

PTPRZ1 (Protein tyrosine phosphatase receptor type Z1)CSPG (Chondroitin sulfate proteoglycan)

Beyond the preview

Go deeper on NVG-291.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVG-291.